Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The physical effects of 5-MeO-MiPT can be broken down into three components all of which progressively intensify proportional to dosage.
The head space of 5-MeO-MiPT is described by many as one which is both insightful and moderately relaxing, but at some points quite stimulating.
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of psilocin, 4-AcO-DMT, or ayahuasca than that of LSD or 2C-B. They can be comprehensively described as structured in their organization, organic in geometric style, intricate in complexity, large in size, fast and smooth in motion, colourful in scheme, glossy in colour, equal in blurred and sharp edges, and equal in rounded and angular corners. At higher dosages, they are significantly more likely to result in states of level 7B visual geometry over level 7A. In terms of their manifestation, they are progressive in nature and continuously self-complexify in settings with little to no visual input and disturbances.
5-MeO-MiPT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics.
The auditory effects of 5-MeO-MiPT are common in their occurrence and exhibit a full range of effects.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
5-MeO-MiPT is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating, though as with most substances, some individuals may use it more frequently than they are comfortable with.
5-MeO-MiPT is not physically addictive. There is no evidence of physical dependence or withdrawal symptoms associated with its use.
There are no known deaths attributed to the use of 5-MeO-MiPT alone. The exact toxic dosage in humans is unknown due to limited history of human use.
Doses approximately 10 times above normal recreational ranges have been shown to induce cell toxicity in brain tissue in animal studies; low-dose use did not cause any serious histopathological effects in this organ.
High doses well above normal ranges have been shown to produce cell toxicity in liver tissue in animal studies; low-dose use did not cause serious histopathological effects.
High doses well above normal ranges have been shown to produce cell toxicity in kidney tissue in animal studies; low-dose use did not cause serious histopathological effects.
Vasoconstriction, increased heart rate, and elevated blood pressure are commonly reported during acute intoxication; cardiac problems including tachycardia and chest pain have been reported particularly after doses exceeding 10 mg.
Temporary psychosis, confusion, disorientation, and agitation have been documented in several clinical case reports, typically associated with high doses or combination with other substances. One case involved a 32-year-old male found disoriented and aggressive after confirmed use. Individuals with a family history of schizophrenia or early onset mental illness should exercise extreme caution as psychedelics can trigger latent psychological problems.
Individuals with seizure or convulsive disorders may be at higher risk for health problems when taking psychedelics, though specific seizure risk data for 5-MeO-MiPT is not available in the literature.
5-MeO-MiPT, commonly known as "Moxy," was first synthesized and characterized in 1985 when David Repke, Donald Grotjahn, and Alexander Shulgin published its synthesis and pharmacological profile in the Journal of Medicinal Chemistry. This publication represented the first known documentation of the…
Could be treated as an illicit analogue under national drug legislation, though not explicitly scheduled.
Production, sale, and possession are prohibited under Portaria SVS/MS nº 344.
Controlled as of September 2015. Illegal to sell, buy, import, export, and manufacture.
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 18, 2019. Production, import with intent to market, administration to others, marketing, and trading are punishable offenses. Possession is illegal but not subject to criminal penalties.
Classified as a Schedule I controlled substance under national drug legislation.
Treated as an analogue of DMT under the Misuse of Drugs Act, classifying it as a Class C controlled drug.
Specifically named as a controlled substance under Verzeichnis E of Swiss drug regulations.
Controlled under the Misuse of Drugs Act 1971 as an ether of 5-HO-MiPT, which falls under the tryptamine catch-all clause. Class A substances carry the most severe penalties.
Prohibited under the Neue Psychoaktive Substanzen Gesetz (New Psychoactive Substances Act). Possession, production, and sale are illegal, though offenders with no intent to distribute may not face prosecution.
Not a scheduled substance, but illegal if sold for human consumption or recreational use.
Banned in December 2014 as part of a government regulation prohibiting over 100 psychoactive chemicals from the consumer market.
Controlled under the Pharmaceutical Affairs Law. Possession and sale are prohibited.
Not listed among prohibited substances, making it technically legal though in a regulatory gray area.
Prohibited along with other tryptamine derivatives as of January 2011.
Classified as a drug. Possession, production, supply, and import are prohibited.
Not scheduled at the federal level, but may be prosecuted under the Federal Analogue Act as an analog of 5-MeO-DiPT (Schedule I) if sold for human consumption. The DEA proposed scheduling in the 2020s but withdrew the proposal amid public opposition. Explicitly Schedule I in Florida, Louisiana (since June 2013), and Minnesota.
14 sources cited
